Neuphoria Therapeutics Inc. (NEUP) stock
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
$2.55−0.03 (-1.16%)
Close on Nov 13, 2026Market cap $76.66KP/E –Yield –
Neuphoria Therapeutics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2026 it was -$3.06.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$3.06 | – |
| FY2025 | Jun 30, 2025 | -$0.23 | – |
| FY2024 | Jun 30, 2024 | -$18.62 | – |
| FY2023 | Jun 30, 2023 | -$43.20 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$0.09 | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$0.77 | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$4.41 | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $6.55 | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$1.79 | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$0.62 | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$2.83 | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$5.31 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?